BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159-165. [PMID: 1855272 DOI: 10.1007/bf00685503] [Cited by in Crossref: 141] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2010; 2(2): 68-75 [PMID: 21160924 DOI: 10.4251/wjgo.v2.i2.68] [Cited by in CrossRef: 140] [Cited by in F6Publishing: 120] [Article Influence: 11.7] [Reference Citation Analysis]
2 Markman M. Clinical Efficacy Supporting the Role of Intraperitoneal Drug Delivery in the Primary Chemotherapeutic Management of Small-Volume Residual Advanced Ovarian Cancer. Seminars in Oncology 2006;33:3-7. [DOI: 10.1053/j.seminoncol.2006.11.002] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, Bertoli P, Busci LM, Lotti M, Cambria F. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112:306-312. [PMID: 25461804 DOI: 10.1038/bjc.2014.602] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 6.5] [Reference Citation Analysis]
4 Sugarbaker PH, Van der Speeten K. Ovarian cancer with peritoneal metastases has many treatment options and HIPEC is here to stay. J Gastrointest Oncol 2021;12:S189-90. [PMID: 33970163 DOI: 10.21037/jgo-2020-17] [Reference Citation Analysis]
5 Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235-41. [PMID: 8297720 DOI: 10.1038/bjc.1994.45] [Cited by in Crossref: 106] [Cited by in F6Publishing: 88] [Article Influence: 3.8] [Reference Citation Analysis]
6 Van der Speeten K, Stuart OA, Sugarbaker PH. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol. 2009;6:72-81. [PMID: 19275544 DOI: 10.2174/157016309787581084] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
7 Nowacki M, Peterson M, Kloskowski T, McCabe E, Guiral DC, Polom K, Pietkun K, Zegarska B, Pokrywczynska M, Drewa T, Roviello F, Medina EA, Habib SL, Zegarski W. Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. Oncotarget 2017;8:78208-24. [PMID: 29100461 DOI: 10.18632/oncotarget.20596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mikolajczyk A, Khosrawipour T, Martino A, Kulas J, Pieczka M, Zacharski M, Nicpon J, Khosrawipour V. Enabling Microparticle Imprinting to Achieve Penetration and Local Endurance in the Peritoneum via High-Intensity Ultrasound (HIUS) for the Treatment of Peritoneal Metastasis. Int J Surg Oncol 2020;2020:9679385. [PMID: 32953172 DOI: 10.1155/2020/9679385] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Sandulache VC, Chen Y, Feng L, William WN, Skinner HD, Myers JN, Meyn RE, Li J, Mijiti A, Bankson JA, Fuller CD, Konopleva MY, Lai SY. Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget 2017;8:18154-65. [PMID: 28184025 DOI: 10.18632/oncotarget.15186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
10 Jandial DD, Messer K, Farshchi-Heydari S, Pu M, Howell SB. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol. 2009;115:362-366. [PMID: 19775736 DOI: 10.1016/j.ygyno.2009.08.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
11 Van der Speeten K, Govaerts K, Stuart OA, Sugarbaker PH. Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients. Gastroenterol Res Pract 2012;2012:378064. [PMID: 22778722 DOI: 10.1155/2012/378064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
12 Macrì A, Fortugno A, Saladino E. Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. World J Gastrointest Oncol 2011; 3(12): 169-174 [PMID: 22224171 DOI: 10.4251/wjgo.v3.i12.169] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
13 Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2010; 2(1): 19-30 [PMID: 21160813 DOI: 10.4251/wjgo.v2.i1.19] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
14 Mangieri CW, Moaven O, Valenzuela CD, Erali RA, Votanopoulos KI, Shen P, Levine EA. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery. J Surg Oncol 2021. [PMID: 34841542 DOI: 10.1002/jso.26759] [Reference Citation Analysis]
15 Wei ZG, Li GX, Huang XC, Zhen L, Yu J, Deng HJ, Qing SH, Zhang C. Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. World J Gastroenterol 2008; 14(14): 2179-2186 [PMID: 18407591 DOI: 10.3748/wjg.14.2179] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
16 Speeten KVD, Stuart AO, Sugarbaker PH. Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer. World J Obstet Gynecol 2013; 2(4): 143-152 [DOI: 10.5317/wjog.v2.i4.143] [Reference Citation Analysis]
17 El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6:117-127. [PMID: 15140400 DOI: 10.1593/neo.03205] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
18 Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Mitomycin or Carboplatin for Diffuse Malignant Peritoneal Mesothelioma. The American Surgeon 2014;80:348-52. [DOI: 10.1177/000313481408000415] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cowan SW, Pechet TT. Pleurectomy and decortication for malignant mesothelioma. Thorac Surg Clin 2004;14:517-21. [PMID: 15559058 DOI: 10.1016/S1547-4127(04)00110-0] [Reference Citation Analysis]
20 Mangeolle T, Yakavets I, Marchal S, Debayle M, Pons T, Bezdetnaya L, Marchal F. Fluorescent Nanoparticles for the Guided Surgery of Ovarian Peritoneal Carcinomatosis. Nanomaterials (Basel) 2018;8:E572. [PMID: 30050022 DOI: 10.3390/nano8080572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
21 Yonemura Y, Ishibashi H, Mizumoto A, Tukiyama G, Liu Y, Wakama S, Sako S, Takao N, Kitai T, Katayama K, Kamada Y, Taniguchi K, Fujimoto D, Endou Y, Miura M. The Development of Peritoneal Metastasis from Gastric Cancer and Rationale of Treatment According to the Mechanism. JCM 2022;11:458. [DOI: 10.3390/jcm11020458] [Reference Citation Analysis]
22 Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther 2008;327:673-82. [PMID: 18780831 DOI: 10.1124/jpet.108.140095] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 4.7] [Reference Citation Analysis]
23 Melis A, Abboud K, Bourmaud A, Pacaut C, Bageacu S, Jacquin JP, Porcheron J, Merrouche Y, Magné N. Reappraisal of the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer: a single institutional experience. Bull Cancer 2011. [PMID: 21659062 DOI: 10.1684/bdc.2011.1371] [Reference Citation Analysis]
24 Markman M. Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin. Ther Clin Risk Manag 2009;5:161-8. [PMID: 19436618 DOI: 10.2147/tcrm.s4186] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
25 de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum 2017;2:47-62. [PMID: 30911633 DOI: 10.1515/pp-2017-0010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
26 Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996;224:405-14; discussion 414-7. [PMID: 8813269 DOI: 10.1097/00000658-199609000-00017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 1.7] [Reference Citation Analysis]